Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers

Breast Cancer Research

Volumn 15, Issue 5, 2013, Pages

  Bianchini, Giampaolo ^a   Pusztai, Lajos ^b   Karn, Thomas ^c   Iwamoto, Takayuki ^d   Rody, Achim ^e   Kelly, Catherine M ^f   Müller, Volkmar ^g   Schmidt, Marcus ^h   Qi, Yuan ⁱ   Holtrich, Uwe ⁱ   Becker, Sven ⁱ   Santarpia, Libero ^j   Fasolo, Angelica ^a   Del Conte, Gianluca ^a   Zambetti, Milvia ^a   Sotiriou, Christos ^k   Haibe Kains, Benjamin ^l   Symmans, W F ⁱ   Gianni, Luca ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b YALE CANCER CENTER   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d OKAYAMA UNIVERSITY   (Japan)

^e UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^f MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^g UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^h JOHANNES GUTENBERG UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF TEXAS   (United States)

^j ISTITUTO TOSCANO TUMORI   (Italy)

^k JULES BORDET INSTITUTE   (Belgium)

^l CLIN RESEARCH INSTITUTE OF MONTREAL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN RECEPTOR; LETROZOLE; TAMOXIFEN; TUMOR MARKER; ESTROGEN; MESSENGER RNA; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CHRONOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HEALTH HAZARD; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; PREDICTIVE VALUE; QUALITATIVE RESEARCH; RISK ASSESSMENT; SCORING SYSTEM; SIGNAL TRANSDUCTION; TREATMENT DURATION; TREATMENT RESPONSE; BREAST CANCER; CELL PROLIFERATION; DOWN REGULATION; DRUG EFFICACY; DRUG RESPONSE; RECURRENCE RISK; RISK FACTOR; ADJUVANT CHEMORADIOTHERAPY; AGED; BREAST TUMOR; CANCER GRADING; CANCER STAGING; FEMALE; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; MIDDLE AGED; MITOSIS; MORTALITY; PATHOLOGY; PROGNOSIS; RISK; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMORADIOTHERAPY, ADJUVANT; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; MITOSIS; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, ESTROGEN; RISK; SIGNAL TRANSDUCTION; TAMOXIFEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84884364251     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3481     Document Type: Article

References (35)

1. Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol 2012, 30:718-721. 10.1200/JCO.2010.34.4010, 3295549, 22042967.
2. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Alencar VHM, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou M-F, Inbar M, Khaled H, Kielanowska J, Kwan W-H, Mathew BS, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Rajan B, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 2013, 381:805-816. 10.1016/S0140-6736(12)61963-1, 3596060, 23219286.
3. Amir E, Seruga B, Niraula S, Carlsson L, Ocana A. Toxicity of adjuvant endocrine therapy in postmenopausal breast cancer patients: a systematic review and meta-analysis. J Natl Cancer Inst 2011, 103:1299-1309. 10.1093/jnci/djr242, 21743022.
4. Albain KS, Barlow WE, Shak S, Hortobagyi GN, Livingston RB, Yeh IT, Ravdin P, Bugarini R, Baehner FL, Davidson NE, Sledge GW, Winer EP, Hudis C, Ingle JN, Perez EA, Pritchard KI, Shepherd L, Gralow JR, Yoshizawa C, Allred DC, Osborne CK, Hayes DF. Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 2010, 11:55-65. 10.1016/S1470-2045(09)70314-6, 3058239, 20005174.
5. Nielsen TO, Parker JS, Leung S, Voduc D, Ebbert M, Vickery T, Davies SR, Snider J, Stijleman IJ, Reed J, Cheang MC, Mardis ER, Perou CM, Bernard PS, Ellis MJ. A comparison of PAM50 intrinsic subtyping with immunohistochemistry and clinical prognostic factors in tamoxifen-treated estrogen receptor-positive breast cancer. Clin Cancer Res 2010, 16:5222-5232. 10.1158/1078-0432.CCR-10-1282, 2970720, 20837693.
6. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, Ellis P, Harris A, Bergh J, Foekens JA, Klijn JG, Larsimont D, Buyse M, Bontempi G, Delorenzi M, Piccart MJ, Sotiriou C. Definition of clinically distinct molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol 2007, 25:1239-1246. 10.1200/JCO.2006.07.1522, 17401012.
7. Loi S, Haibe-Kains B, Desmedt C, Wirapati P, Lallemand F, Tutt AM, Gillet C, Ellis P, Ryder K, Reid JF, Daidone MG, Pierotti MA, Berns EM, Jansen MP, Foekens JA, Delorenzi M, Bontempi G, Piccart MJ, Sotiriou C. Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen. BMC Genomics 2008, 9:239. 10.1186/1471-2164-9-239, 2423197, 18498629.
8. Symmans WF, Hatzis C, Sotiriou C, Andre F, Peintinger F, Regitnig P, Daxenbichler G, Desmedt C, Domont J, Marth C, Delaloge S, Bauernhofer T, Valero V, Booser DJ, Hortobagyi GN, Pusztai L. Genomic index of sensitivity to endocrine therapy for breast cancer. J Clin Oncol 2010, 28:4111-4119. 10.1200/JCO.2010.28.4273, 2953969, 20697068.
9. Zhang Y, Sieuwerts AM, McGreevy M, Casey G, Cufer T, Paradiso A, Harbeck N, Span PN, Hicks DG, Crowe J, Tubbs RR, Budd GT, Lyons J, Sweep FC, Schmitt M, Schittulli F, Golouh R, Talantov D, Wang Y, Foekens JA. The 76-gene signature defines high-risk patients that benefit from adjuvant tamoxifen therapy. Breast Cancer Res Treat 2009, 116:303-309. 10.1007/s10549-008-0183-2, 18821012.
10. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T, Berns EM, Atkins D, Foekens JA. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005, 365:671-679.
11. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B, Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ, Buyse M, Sotiriou C. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin Cancer Res 2007, 13:3207-3214. 10.1158/1078-0432.CCR-06-2765, 17545524.
12. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, Lehr HA, Hengstler JG, Kolbl H, Gehrmann M. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res 2008, 68:5405-5413. 10.1158/0008-5472.CAN-07-5206, 18593943.
13. Minn AJ, Gupta GP, Padua D, Bos P, Nguyen DX, Nuyten D, Kreike B, Zhang Y, Wang Y, Ishwaran H, Foekens JA, van de Vijver M, Massague J. Lung metastasis genes couple breast tumor size and metastatic spread. Proc Natl Acad Sci USA 2007, 104:6740-6745. 10.1073/pnas.0701138104, 1871856, 17420468.
14. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Cardoso F, Peterse H, Nuyten D, Buyse M, Van de Vijver MJ, Bergh J, Piccart M, Delorenzi M. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 2006, 98:262-272. 10.1093/jnci/djj052, 16478745.
15. Filipits M, Rudas M, Jakesz R, Dubsky P, Fitzal F, Singer CF, Dietze O, Greil R, Jelen A, Sevelda P, Freibauer C, Muller V, Janicke F, Schmidt M, Kolbl H, Rody A, Kaufmann M, Schroth W, Brauch H, Schwab M, Fritz P, Weber KE, Feder IS, Hennig G, Kronenwett R, Gehrmann M, Gnant M. A new molecular predictor of distant recurrence in ER-positive, HER2-negative breast cancer adds independent information to conventional clinical risk factors. Clin Cancer Res 2011, 17:6012-6020. 10.1158/1078-0432.CCR-11-0926, 21807638.
16. Miller WR, Larionov A, Anderson TJ, Evans DB, Dixon JM. Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole. Pharmacogenomics J 2012, 12:10-21. 10.1038/tpj.2010.67, 20697427.
17. Bianchini G, Iwamoto T, Qi Y, Coutant C, Shiang CY, Wang B, Santarpia L, Valero V, Hortobagyi GN, Symmans WF, Gianni L, Pusztai L. Prognostic and therapeutic implications of distinct kinase expression patterns in different subtypes of breast cancer. Cancer Res 2010, 70:8852-8862. 10.1158/0008-5472.CAN-10-1039, 20959472.
18. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
19. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS. Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 2009, 27:1160-1167. 10.1200/JCO.2008.18.1370, 2667820, 19204204.
20. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009. 10.1056/NEJMoa021967, 12490681.
21. Haibe-Kains B, Desmedt C, Loi S, Culhane AC, Bontempi G, Quackenbush J, Sotiriou C. A three-gene model to robustly identify breast cancer molecular subtypes. J Natl Cancer Inst 2012, 104:311-325. 10.1093/jnci/djr545, 3283537, 22262870.
22. Simon R, Lam A, Li MC, Ngan M, Menenzes S, Zhao Y. Analysis of gene expression data using BRB-ArrayTools. Cancer Inform 2007, 3:11-17. 2675854, 19455231.
23. Hess KR, Serachitopol DM, Brown BW. Hazard function estimators: a simulation study. Stat Med 1999, 18:3075-3088. 10.1002/(SICI)1097-0258(19991130)18:22<3075::AID-SIM244>3.0.CO;2-6, 10544307.
24. Jatoi I, Anderson WF, Jeong JH, Redmond CK. Breast cancer adjuvant therapy: time to consider its time-dependent effects. J Clin Oncol 2011, 29:2301-2304. 10.1200/JCO.2010.32.3550, 3107746, 21555693.
25. Bellera C, MacGrogan G, Debled M, de Lara C, Brouste V, Mathoulin-Pelissier S. Variables with time-varying effects and the Cox model: Some statistical concepts illustrated with a prognostic factor study in breast cancer. BMC Med Res Methodol 2010, 10:20. 10.1186/1471-2288-10-20, 2846954, 20233435.
26. Kim C, Tang G, Pogue-Geile KL, Costantino JP, Baehner FL, Baker J, Cronin MT, Watson D, Shak S, Bohn OL, Fumagalli D, Taniyama Y, Lee A, Reilly ML, Vogel VG, McCaskill-Stevens W, Ford LG, Geyer CE, Wickerham DL, Wolmark N, Paik S. Estrogen receptor (ESR1) mRNA expression and benefit from tamoxifen in the treatment and prevention of estrogen receptor-positive breast cancer. J Clin Oncol 2011, 29:4160-4167. 10.1200/JCO.2010.32.9615, 3208536, 21947828.
27. Ellis MJ, Tao Y, Luo J, A'Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 2008, 100:1380-1388. 10.1093/jnci/djn309, 2556704, 18812550.
28. van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet 2011, 377:321-331. 10.1016/S0140-6736(10)62312-4, 21247627.
29. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Lang I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thurlimann B. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 2011, 12:1101-1108. 10.1016/S1470-2045(11)70270-4, 3235950, 22018631.
30. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353:2747-2757.
31. Dowsett M, Cuzick J, Ingle J, Coates A, Forbes J, Bliss J, Buyse M, Baum M, Buzdar A, Colleoni M, Coombes C, Snowdon C, Gnant M, Jakesz R, Kaufmann M, Boccardo F, Godwin J, Davies C, Peto R. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 2010, 28:509-518. 10.1200/JCO.2009.23.1274, 19949017.
32. Tang G, Cuzick J, Costantino JP, Dowsett M, Forbes JF, Crager M, Mamounas EP, Shak S, Wolmark N. Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors. J Clin Oncol 2011, 29:4365-4372. 10.1200/JCO.2011.35.3714, 3221521, 22010013.
33. Bianchini G, Qi Y, Alvarez RH, Iwamoto T, Coutant C, Ibrahim NK, Valero V, Cristofanilli M, Green MC, Radvanyi L, Hatzis C, Hortobagyi GN, Andre F, Gianni L, Symmans WF, Pusztai L. Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers. J Clin Oncol 2010, 28:4316-4323. 10.1200/JCO.2009.27.2419, 20805453.
34. Sgroi D, Sestak I, Cuzick J, Zhang Y, Schnabel C, Erlander M, Goss P, Dowsett M. Comparative performance of breast cancer index (bci) vs. oncotype dx and ihc4 in the prediction of late recurrence in hormonal receptor-positive lymph node-negative breast cancer patients: a TransATAC study. Cancer Res 2012, 72:S1-9.
35. Dubsky P, Brase JC, Fisch K, Jakesz R, Singer CF, Greil R, Dietze O, Weber KE, Petry C, Kronenwett R, Rudas M, Knauer M, Gnant M. The EndoPredict score identifies late distant metastases in ER+/HER2- breast cancer patients. Cancer Res 2012, 72:S4-3.